Connect Biopharma expects topline results from its Phase 2 Seabreeze STAT studies in September 2026.
The trials evaluate lead candidate rademikibart for treating acute exacerbations in asthma and Chronic Obstructive Pulmonary Disease (COPD).
Investors view the upcoming data readout as a key inflection point for the company.
The studies assess treatment failure rates and lung function improvements to validate the drug's efficacy.
Connect Biopharma plans to discuss a potential Phase 3 program with the FDA following the results.